A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia

Ali I. Al-Bahrani, Charles S. Bakhiet, Riad A. Bayoumi, Said A. Al-Yahyaee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Diabetic dyslipidaemia is characterised by retention of atherogenic particles, which are depleted of cholesterol. Therefore, calculating or measuring LDL or VLDL cholesterol may not reflect the actual number of these atherogenic particles. We examined the potential role of apolipoprotein B in the risk stratification of Omani patients with type 2 diabetes and dyslipidaemia. Two hundred and twenty-one subjects with type 2 diabetes and 67 healthy controls were recruited. Diabetic subjects had significantly higher serum levels of triglycerides (P < 0.0001), non-HDL cholesterol (P < 0.0001), and total/HDL cholesterol ratio (P < 0.04) and lower levels of HDL cholesterol (P < 0.0001) and lipoprotein(a) compared to nondiabetic subjects. The ratio of apoB/LDL cholesterol ratio was significantly higher (P < 0.002) among diabetic compared to nondiabetic subjects. Sixty percent of the diabetic subjects with abnormal apoB of >1.2 g/L had an LDL cholesterol of less than 4.2 mmol/L compared to 7% of the nondiabetic subjects (sensitivity; 40% versus 93%, respectively). Furthermore, diabetic subjects with ischaemic heart disease (IHD) had significantly higher (P < 0.003) apoB/non-HDL cholesterol ratio compared to those without IHD. These findings suggest that the ratios of apoB/LDL cholesterol and apoB/non-HDL cholesterol may have a role in the risk stratification of diabetic patients with dyslipidaemia.

Original languageEnglish
Pages (from-to)44-51
Number of pages8
JournalDiabetes Research and Clinical Practice
Volume69
Issue number1
DOIs
Publication statusPublished - Jul 2005

Fingerprint

Apolipoproteins B
Dyslipidemias
LDL Cholesterol
Cholesterol
Type 2 Diabetes Mellitus
Myocardial Ischemia
VLDL Cholesterol
Triglycerides
Serum

Keywords

  • Apolipoprotein B
  • Dyslipidaemia
  • Ischaemic heart disease
  • Oman
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia. / Al-Bahrani, Ali I.; Bakhiet, Charles S.; Bayoumi, Riad A.; Al-Yahyaee, Said A.

In: Diabetes Research and Clinical Practice, Vol. 69, No. 1, 07.2005, p. 44-51.

Research output: Contribution to journalArticle

@article{72b028c2f0c94fa39b665768b6d7a925,
title = "A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia",
abstract = "Diabetic dyslipidaemia is characterised by retention of atherogenic particles, which are depleted of cholesterol. Therefore, calculating or measuring LDL or VLDL cholesterol may not reflect the actual number of these atherogenic particles. We examined the potential role of apolipoprotein B in the risk stratification of Omani patients with type 2 diabetes and dyslipidaemia. Two hundred and twenty-one subjects with type 2 diabetes and 67 healthy controls were recruited. Diabetic subjects had significantly higher serum levels of triglycerides (P < 0.0001), non-HDL cholesterol (P < 0.0001), and total/HDL cholesterol ratio (P < 0.04) and lower levels of HDL cholesterol (P < 0.0001) and lipoprotein(a) compared to nondiabetic subjects. The ratio of apoB/LDL cholesterol ratio was significantly higher (P < 0.002) among diabetic compared to nondiabetic subjects. Sixty percent of the diabetic subjects with abnormal apoB of >1.2 g/L had an LDL cholesterol of less than 4.2 mmol/L compared to 7{\%} of the nondiabetic subjects (sensitivity; 40{\%} versus 93{\%}, respectively). Furthermore, diabetic subjects with ischaemic heart disease (IHD) had significantly higher (P < 0.003) apoB/non-HDL cholesterol ratio compared to those without IHD. These findings suggest that the ratios of apoB/LDL cholesterol and apoB/non-HDL cholesterol may have a role in the risk stratification of diabetic patients with dyslipidaemia.",
keywords = "Apolipoprotein B, Dyslipidaemia, Ischaemic heart disease, Oman, Type 2 diabetes mellitus",
author = "Al-Bahrani, {Ali I.} and Bakhiet, {Charles S.} and Bayoumi, {Riad A.} and Al-Yahyaee, {Said A.}",
year = "2005",
month = "7",
doi = "10.1016/j.diabres.2004.09.011",
language = "English",
volume = "69",
pages = "44--51",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia

AU - Al-Bahrani, Ali I.

AU - Bakhiet, Charles S.

AU - Bayoumi, Riad A.

AU - Al-Yahyaee, Said A.

PY - 2005/7

Y1 - 2005/7

N2 - Diabetic dyslipidaemia is characterised by retention of atherogenic particles, which are depleted of cholesterol. Therefore, calculating or measuring LDL or VLDL cholesterol may not reflect the actual number of these atherogenic particles. We examined the potential role of apolipoprotein B in the risk stratification of Omani patients with type 2 diabetes and dyslipidaemia. Two hundred and twenty-one subjects with type 2 diabetes and 67 healthy controls were recruited. Diabetic subjects had significantly higher serum levels of triglycerides (P < 0.0001), non-HDL cholesterol (P < 0.0001), and total/HDL cholesterol ratio (P < 0.04) and lower levels of HDL cholesterol (P < 0.0001) and lipoprotein(a) compared to nondiabetic subjects. The ratio of apoB/LDL cholesterol ratio was significantly higher (P < 0.002) among diabetic compared to nondiabetic subjects. Sixty percent of the diabetic subjects with abnormal apoB of >1.2 g/L had an LDL cholesterol of less than 4.2 mmol/L compared to 7% of the nondiabetic subjects (sensitivity; 40% versus 93%, respectively). Furthermore, diabetic subjects with ischaemic heart disease (IHD) had significantly higher (P < 0.003) apoB/non-HDL cholesterol ratio compared to those without IHD. These findings suggest that the ratios of apoB/LDL cholesterol and apoB/non-HDL cholesterol may have a role in the risk stratification of diabetic patients with dyslipidaemia.

AB - Diabetic dyslipidaemia is characterised by retention of atherogenic particles, which are depleted of cholesterol. Therefore, calculating or measuring LDL or VLDL cholesterol may not reflect the actual number of these atherogenic particles. We examined the potential role of apolipoprotein B in the risk stratification of Omani patients with type 2 diabetes and dyslipidaemia. Two hundred and twenty-one subjects with type 2 diabetes and 67 healthy controls were recruited. Diabetic subjects had significantly higher serum levels of triglycerides (P < 0.0001), non-HDL cholesterol (P < 0.0001), and total/HDL cholesterol ratio (P < 0.04) and lower levels of HDL cholesterol (P < 0.0001) and lipoprotein(a) compared to nondiabetic subjects. The ratio of apoB/LDL cholesterol ratio was significantly higher (P < 0.002) among diabetic compared to nondiabetic subjects. Sixty percent of the diabetic subjects with abnormal apoB of >1.2 g/L had an LDL cholesterol of less than 4.2 mmol/L compared to 7% of the nondiabetic subjects (sensitivity; 40% versus 93%, respectively). Furthermore, diabetic subjects with ischaemic heart disease (IHD) had significantly higher (P < 0.003) apoB/non-HDL cholesterol ratio compared to those without IHD. These findings suggest that the ratios of apoB/LDL cholesterol and apoB/non-HDL cholesterol may have a role in the risk stratification of diabetic patients with dyslipidaemia.

KW - Apolipoprotein B

KW - Dyslipidaemia

KW - Ischaemic heart disease

KW - Oman

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=20444471479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444471479&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2004.09.011

DO - 10.1016/j.diabres.2004.09.011

M3 - Article

C2 - 15904989

AN - SCOPUS:20444471479

VL - 69

SP - 44

EP - 51

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 1

ER -